263 related articles for article (PubMed ID: 34444777)
41. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
[TBL] [Abstract][Full Text] [Related]
42. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
43. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
44. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.
Poupon R; Poupon RE
Pharmacol Ther; 1995 Apr; 66(1):1-15. PubMed ID: 7630925
[TBL] [Abstract][Full Text] [Related]
46. Therapy with ursodeoxycholic acid in cholestatic liver disease.
Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
[TBL] [Abstract][Full Text] [Related]
47. Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70
de Vries HD; Palmiotti A; Li R; Hovingh MV; Mulder NL; Koehorst M; Bloks VW; van Zutphen T; Kuipers F; de Boer JF
Pediatr Res; 2023 May; 93(6):1582-1590. PubMed ID: 36151295
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
49. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
50. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
51. n-3 Fatty Acids Abrogate Dyslipidemia-Induced Changes in Bile Acid Uptake, Synthesis, and Transport in Young and Aged Dyslipidemic Rats.
Acharya P; Talahalli RR
Lipids; 2019 Jan; 54(1):39-51. PubMed ID: 30740707
[TBL] [Abstract][Full Text] [Related]
52. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
53. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
54. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
55. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
56. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
57. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
58. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
59. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.
Beuers U; Spengler U; Zwiebel FM; Pauletzki J; Fischer S; Paumgartner G
Hepatology; 1992 Apr; 15(4):603-8. PubMed ID: 1551637
[TBL] [Abstract][Full Text] [Related]
60. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
